OmniAb, Inc. OABI
4.85 USD -0.25 (-5.00%)
Nov 12, 2026, 12:50 PM EST
4.73 Day range 5.08
1.35 52-week range 5.45
- YTD
- +161.89%
- 1 year
- +208.60%
News
benzinga.com OmniAb Q3 2026 Earnings Call Transcript OmniAb (NASDAQ:OABI) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
benzinga.com OmniAb Q3 EPS $(0.12), Inline, Sales $3.993M Beat $3.492M Estimate OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.14) per share from the same period…
benzinga.com OmniAb Raises FY2026 Sales Guidance from $32.000M-$36.000M to $35.000M-$39.000M vs $35.036M Est OmniAb (NASDAQ:OABI) raises FY2026 sales outlook from $32.000 million-$36.000 million to $35.000 million-$39.000 million vs $35.036 million estimate.
benzinga.com Leerink Partners Maintains Outperform on OmniAb, Raises Price Target to $12 Leerink Partners analyst Puneet Souda maintains OmniAb (NASDAQ:OABI) with a Outperform and raises the price target from $10 to $12.
benzinga.com StoneX Maintains Buy on OmniAb, Raises Price Target to $6 StoneX analyst Robert Wasserman maintains OmniAb (NASDAQ:OABI) with a Buy and raises the price target from $4 to $6.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares…
benzinga.com Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
benzinga.com HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.
benzinga.com Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consumer staples down 1%. NY Fed's Empire State Index at 20.6.
benzinga.com H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.
benzinga.com Why Is Omniab Stock Rallying After Eli Lilly Deal? The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved…
benzinga.com Market-Moving News for August 17th HIVE: 9% | HIVE's BUZZ HPC Signs $350M Five-Year AI Cloud Deal With Investment-Grade Customer, Adding $70M ARR To Reach $180M Total Annualized Revenue OABI: 33% | OmniAb Announces Global…
benzinga.com Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 results and raised FY26 sales guidance. Other big gains include DOCS, QNST, TEAM, CRSR, OABI, PUBM, TWLO,…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out…- benzinga.com OmniAb Raises FY2026 Sales Guidance from $28.000M-$33.000M to $32.000M-$36.000M vs $30.807M Est OmniAb (NASDAQ:OABI) raises FY2026 sales outlook from $28.000 million-$33.000 million to $32.000 million-$36.000 million vs $30.807 million estimate.
benzinga.com OmniAb Q2 EPS $(0.05) Beats $(0.12) Estimate, Sales $13.415M Beat $4.693M Estimate OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.12) by 58.33 percent. This is a 66.67 percent increase over losses of $(0.15) per…- benzinga.com VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222,
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com OmniAb Q4 Earnings Assessment - benzinga.com OmniAb Q4 EPS $(0.11) Misses $(0.09) Estimate, Sales $8.376M Miss $9.003M Estimate OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 23.6 percent. This is a 8.33 percent increase over losses of $(0.12) per…
benzinga.com Earnings Scheduled For March 4, 2026 
benzinga.com A Look Ahead: OmniAb's Earnings Forecast - benzinga.com OmniAb And Arrowmark Partners Sign A License And Services Agreement For Novel OmniAb-Derived Antibody Discovery Programs With Mabtrx Biosciences; OmniAb To Receive Revenue For Discovery Services As Well As Potential Equity And Royalties OmniAb, Inc. (NASDAQ:OABI) and ArrowMark Partners ("ArrowMark") today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx…
- benzinga.com OmniAb Lowers FY2025 Sales Guidance from $20.000M-$25.000M to $18.000M-$22.000M vs $21.657M Est OmniAb (NASDAQ:OABI) lowers FY2025 sales outlook from $20.000 million-$25.000 million to $18.000 million-$22.000 million vs $21.657 million estimate.
- benzinga.com OmniAb Q3 EPS $(0.14), Inline, Sales $2.239M Miss $5.644M Estimate OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 12.5 percent increase over losses of $(0.16) per share from the same period…
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Top 3 Health Care Stocks You'll Regret Missing This Quarter - benzinga.com RBC Capital Maintains Outperform on OmniAb, Lowers Price Target to $3 RBC Capital analyst Conor McNamara maintains OmniAb (NASDAQ:OABI) with a Outperform and lowers the price target from $4 to $3.
- benzinga.com CORRECTION: OmniAb Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $3.897M Miss $5.334M Estimate OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 4.46 percent. This is a 15.38 percent decrease over losses of $(0.13) per…
- benzinga.com OmniAb Affirms FY2025 Sales Guidance of $20.000M-$25.000M vs $22.970M Est OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.000 million-$25.000 million to $20.000 million-$25.000 million vs $22.970 million estimate.
- benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Benchmark Reiterates Buy on OmniAb, Maintains $6 Price Target Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $6 price target.
- benzinga.com OmniAb Affirms FY2025 Sales Guidance of $20.00M-$25.00M vs $22.89M Est OmniAb (NASDAQ:OABI) affirms FY2025 sales outlook from $20.00 million-$25.00 million to $20.00 million-$25.00 million vs $22.89 million estimate.
benzinga.com OmniAb Q1 EPS $(0.17) Misses $(0.16) Estimate, Sales $4.15M Miss $4.49M Estimate OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.16) by 6.25 percent. This is a 10.53 percent increase over losses of $(0.19) per…- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com VERAXA Biotech Joins Forces with OmniAb to Develop Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors Under the terms of the agreement, VERAXA will initiate a novel bispecific antibody drug conjugate program addressing two attractive target molecules in cancer medicine. The Company will utilize…
- benzinga.com RBC Capital Maintains Outperform on OmniAb, Lowers Price Target to $4 RBC Capital analyst Conor McNamara maintains OmniAb (NASDAQ:OABI) with a Outperform and lowers the price target from $7 to $4.
- benzinga.com Benchmark Maintains Buy on OmniAb, Lowers Price Target to $6 Benchmark analyst Robert Wasserman maintains OmniAb (NASDAQ:OABI) with a Buy and lowers the price target from $8 to $6.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Dow Surges Over 200 Points; US Crude Oil Inventories Increase More than Expected - benzinga.com HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com OmniAb Q4 2024 GAAP EPS $(0.12) Misses $(0.11) Estimate, Sales $10.80M Beat $10.13M Estimate OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 14.29 percent increase over losses of $(0.14) per…
- benzinga.com Earnings Scheduled For March 18, 2025
- benzinga.com Benchmark Reiterates Buy on OmniAb, Maintains $8 Price Target Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $8 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.